SYNGENE Ltd.

330.55.00INR + 2.65 (+ 0.81%) VOLUME : 101000
    Average Volume
  • 5-Day 105,800.00
  • 20-Day 134,199.90
  • 3-Months 117,076.85

MARKET CLOSED

Price Table

Date Open High GREEN: if High is higher than last 2 days high
RED: if high is lower than last 2 days high
Low GREEN:if Low is higher than last 2 days low
RED: if low is lower than last 2 days low
LTP Close GREEN:if Day's Closing is near the Day's High
RED: if low is lower than last 2 days low
Volume Delivery % 20 Day SMA GREEN: if Day's Closing is above 20-Day SMA
RED: if Day's Closing is below 20-Day SMA
50 Day SMA GREEN: if Day's Closing is above 50-Day SMA
RED: if Day's Closing is below 50-Day SMA
100 Day SMA GREEN: if Day's Closing is above 100-Day SMA
RED: if Day's Closing is below 100-Day SMA
200 Day SMA GREEN: if Day's Closing is above 200-Day SMA
RED: if Day's Closing is below 200-Day SMA
18-Oct-19 324.60 334.50 324.60 330.55 332.25 100,886 71% 314.49 311.75 357.84 470.56
17-Oct-19 326.55 329.00 323.25 328.00 327.90 43,160 66% 313.36 311.09 360.67 471.71
16-Oct-19 325.55 331.65 319.75 326.00 326.70 83,283 46% 312.28 310.57 363.44 472.87
15-Oct-19 315.05 333.00 315.05 325.00 325.55 217,681 63% 311.80 310.14 366.20 474.09
14-Oct-19 313.60 316.00 309.90 314.60 315.05 83,818 70% 311.55 309.95 368.86 475.30
11-Oct-19 307.30 312.95 303.55 309.40 309.95 244,941 86% 311.84 309.89 371.66 476.57
10-Oct-19 304.15 310.95 303.10 307.30 309.10 366,817 94% 312.76 309.88 374.42 477.86

Performance

Key Data

Day High Low Range

Time Lowest Highest
10 AM 324.60 332.80
11 AM 324.60 332.80
12 PM 324.60 332.80
1 PM 324.60 332.80
2 PM 324.60 332.80

Company Profile - SYNGENE Ltd.

SYNGENE

It was incorporated as Syngene International Private Limited as on November 18, 1993, at Bengaluru, Karnataka as a private limited company under the Companies Act, 1956. According to a special resolution of the shareholders dated March 26, 2007, the Company was being converted into a public limited company, and the company name was changed to Syngene International Limited. Also, a fresh certificate of incorporation consequent upon conversion to the public limited company was issued as on April 19, 2007. It was also promoted by Kiran Mazumdar Shaw, who is a promoter of Biocon. On March 30, 2002, 99.9% of the Equity Shares of the Company were being transferred to Biocon, and as a result, it became the subsidiary of Biocon. It has also since been the Promoter of the Company. Also, the details of changes in the registered office of the Company are given below: From 20th KM, Hosur Road, Electronics City P.O, Bengaluru 560 100, Karnataka, India to Biocon Sp ... ecial Economic Zone, Biocon Park, Plot No. 2 and 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bengaluru 560 099, Karnataka, India.

Some of the Milestones:

  • 1994: It initiated operations as a CRO with services in chemistry and biology.
  • 1998: It granted 100% Export Oriented Unit (EOU) status by the Government of India.
  • 1999: Its first operational expansion in R&D by way of expansion of lab space to over 23,000 sq. Ft.
  • 2000: Also, CIL was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
  • 2001: It forayed into chemical development with a dedicated manufacturing facility.
  • 2003: It moved to Biocon Park, a 90-acre biopharmaceutical SEZ with the operations spread over 65,000 sq. Ft.
  • 2007:
  • Both Bristol-Myers Squibb and the Company signed the first long term contract to set up the first dedicated R&D center.
  • The expansion of research facilities located at Biocon SEZ to 148,000 sq. Ft.
  • It crossed an annual turnover of over `1,000 million in Financial Year 2007.
  • 2009:
  • Both Dupont Crop Protection and the Company extended a partnership for R&D services.
  • The expansion of manufacturing services with a new plant which is cGMP compliant.
  • It initiated operations in safety assessment and large molecules development services.
  • 2010:
  • Also, the acceptance of the clinical and bio-analytical facilities of CIL by the Department of Health & Human Services, FDA.
  • It initiated operations in formulation development.
  • 2011: Both Endo Pharmaceuticals and the Company collaborated to develop novel biological therapeutic molecules against cancer.
  • 2012:
  • Both Abbott and the Company collaborated to establish Abbott's nutrition research and development center in India and the second R&D center.
  • It received the certification of the clinical facilities by ANVISA.
  • It acquired a 100% stake in Clinigene International Limited from Biocon.
  • 2013:
  • It crossed an annual turnover of over INR 5,000 million in Financial Year 2013.
  • Also, the Baxter International Inc. collaborated with the Company to establish the ‘Baxter Global Research Center,’ the third dedicated R&D center.
  • The acceptance of the control testing laboratory by the Department of Health & Human Services, FDA.
  • 2014:
  • Both Bristol-Myers Squibb and the Company extend collaboration for its dedicated R&D center till 2020.
  • The acceptance of the API manufacturing facility by the Department of Health & Human Services, FDA.
  • It also established a 75,000 sq.ft center to provide stability and analytical services.
  • 2015: Also, the CIL was amalgamated with the Company.

Some of the Achievements:

  • 2009:
  • It received Bangalore Bio, Bio Excellence Award, in Biotech Services Sector.
  • It won the Best BioServices Company of the year from Biospectrum.
  • 2012:
  • It received ISO 9001:2008 for contract research in drug discovery and contract manufacturing of biopharmaceuticals.
  • It received AAALAC accreditation for conforming to the “Guide for the Care and Use of Laboratory Animals and the Committee for Control & Supervision of the Experiments on Animals guidelines.”
  • 2013:
  • It received Bioservices - ABLE Tenth Anniversary Award for the outstanding contribution to Bioservices.
  • It received Diamond Sponsor recognition by the Association of Scientists of Indian Origin of the Society of Toxicology.
  • 2014:
  • It received ISO 14001:2004 for contract research in drug discovery and contract manufacturing of biopharmaceuticals.
  • It received BS OHSAS 18001:2007 for contract research in drug discovery and contract manufacturing of biopharmaceuticals.
  • It received a Silver EDGE Award.
  • It received the EHS best practices award by CII.
  • It received SAP Ace Award for special recognition for complex SAP implementation.
  • 2015:
  • Also, the accreditation by the College of American Pathologists concerning their laboratory accreditation program.
  • It received Bangalore India Bio - Bio Excellence Award for an outstanding contribution to the Biotech services sector.
  • It received ISO 15189:2007 in the field of medical testing.
  • 2017:
  • Both Herbalife Nutrition Partners with Syngene to Establish Nutrition Research and Development Lab in India.
  • The "Syngene International Announces Broadening of Research Collaboration with Amgen Inc." and expands the Dedicated R&D Center.
  • Both "Bristol-Myers Squibb and Syngene International Expand for an Ongoing Research Collaboration."